Regulation of bone mass by serotonin: Molecular biology and therapeutic implications

Annual Review of Medicine

Volumn 62, Issue , 2011, Pages 323-331

  Karsenty, Gerard ^a   K Yadav, Vijay ^b  

^a NewYork Presbyterian Hospital   (United States)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

CREB; duodenum; enterochromaffin cells; osteoblasts; proliferation; Tph1

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LP 533401; PROTEIN SYNTHESIS INHIBITOR; SEROTONIN; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; BONE DYSPLASIA; BONE MASS; DRUG MECHANISM; ENTEROCHROMAFFIN CELL; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; NORRIE DISEASE; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANIMALS; BONE DENSITY; CLINICAL TRIALS AS TOPIC; DUODENUM; FEMALE; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MICE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PYRIMIDINES; RATS; SEROTONIN; SEROTONIN ANTAGONISTS; TRYPTOPHAN HYDROXYLASE;

EID: 79551596145     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-med-090710-133426     Document Type: Article

References (28)

1. Gong Y, Slee RB, Fukai N, et al. 2001. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107:513-23
2. Kato M, Patel MS, Levasseur R, et al. 2002. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157:303-14
3. Lobov IB, Rao S, Carroll TJ, et al. 2005. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature 437:417-21
4. Gong Y, Vikkula M, Boon L, et al. 1996. Osteoporosis-pseudoglioma syndrome, a disorder affecting skeletal strength and vision, is assigned to chromosome region 11q12-13. Am. J. Hum. Genet. 59:146-51
5. Boyden LM, Mao J, Belsky J, et al. 2002. High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346:1513-21
6. Johnson ML, Gong G, Kimberling W, et al. 1997. Linkage of a gene causing high bone mass to human chromosome 11(11q12-13). Am. J. Hum. Genet. 60:1326-32
7. Little RD, Carulli JP, Del Mastro RG, et al. 2002. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70:11-19
8. Glass DA, 2nd, Karsenty G. 2007. In vivo analysis of Wnt signaling in bone. Endocrinology 148:2630-34
9. Kikuchi A, Yamamoto H, Kishida S. 2007. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal. 19:659-71
10. Logan CY, Nusse R. 2004. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20:781-810
11. Glass DA, 2nd, Bialek P, Ahn JD, et al. 2005. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8:751-64
12. Yadav VK, Arantes HP, Barros ER, etal. 2010. Genetic analysis of Lrp5 function in osteoblast progenitors. Calcif. Tissue Int. 86:382-88
13. Yadav VK, Ryu JH, Suda N, et al. 2008. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135, 825-37.
14. Kramer I, Halleux C, Keller H, et al. 2010. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol. Cell Biol. 30:3071-85
15. Gershon MD, Tack J. 2007. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology 132:397-414
16. Heath MJ, Hen R. 1995. Serotonin receptors. Genetic insights into serotonin function. Curr. Biol. 5:997-99
17. Mann JJ, McBride PA, Brown RP, et al. 1992. Relationship between central and peripheral serotonin indexes in depressed and suicidal psychiatric inpatients. Arch. Gen. Psychiatry 49:442-46
18. Noda M, Higashida H, Aoki S, et al. 2004. Multiple signal transduction pathways mediated by 5-HT receptors. Mol. Neurobiol. 29:31-39
19. Ramirez Rodriguez S, Morton D, Garcia Merino S, etal. 2010. Elevated serum serotonin levels in patients with osteoporosis-pseudoglioma syndrome. Presented at Endo 2010, June 19-22, San Diego, CA. Abstr. P3-186
20. Saarinen A, Saukkonen T, Kivela T, et al. 2009. LDL receptor-related protein 5 (LRP5) mutations and osteoporosis, impaired glucose metabolism and hypercholesterolaemia. Clin. Endocrinol. (Oxf.) 72:481-88
21. Frost M, Andersen T, Yadav V, et al. 2010. Patients with high bone mass phenotype due to Lrp5-T253I mutation have low plasma levels of serotonin. J. Bone Miner. Res. 25:673-75
22. Giovannini M, Valsasina R, Longhi R, et al. 1988. Serotonin and noradrenaline concentrations and serotonin uptake in platelets from hyperphenylalaninaemic patients. J. Inherit. Metab. Dis. 11:285-90
23. Modan-Moses D, Vered I, Schwartz G, et al. 2007. Peak bone mass in patients with phenylketonuria. J. Inherit. Metab. Dis. 30:202-8
24. Liu Q, Yang Q, Sun W, et al. 2008. Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract. J. Pharmacol. Exp. Ther. 325:47-55
25. Yadav VK, Balaji S, Suresh PS, et al. 2010. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med. 16:308-12
26. Yadav VK, Oury F, Suda N, et al. 2009. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 138:976-89
27. Bilezikian JP, Matsumoto T, Bellido T, et al. 2009. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J. Bone Miner. Res. 24:373-85
28. Rodan GA, Martin TJ. 2000. Therapeutic approaches to bone diseases. Science 289:1508-14